11月 2025
- 首頁
- Glenmark Pharmaceuticals Limited
11月 2025Glenmark Pharmaceuticals...的市場佔有率分析
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, India.
顯示Glenmark Pharmaceuticals Limited的主要網站流量和參與度資訊(包含公司地區)
查看更多網站流量與參與度資訊- glenmarkpharma.com
- glenmarkpharma-us.com
- glenmarkpharma.com.br
Glenmark Pharmaceuticals Limited截至 11月 2025 的總收入為 > 1B
Glenmark Pharmaceuticals Limited 熱門網域產生的總收入
Glenmark Pharmaceuticals Limited 熱門網域 3 年內的總收入
Glenmark Pharmaceuticals Limited 熱門網域的總收入
11月 2025Glenmark Pharmaceuticals Limited的股票價格
Glenmark Pharmaceuticals Limited 股票交易代碼 #GLENMARK。以下是截至 11月 2025Glenmark Pharmaceuticals Limited 過去 12 個月的股票績效
Glenmark Pharmaceuticals Limited的熱門網域總造訪量
了解Glenmark Pharmaceuticals Limited市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
Glenmark Pharmaceuticals Limited的熱門網域平均造訪時長
分析Glenmark Pharmaceuticals Limited參與度指標。
過去 3 個月平均造訪時長
子公司細目
Glenmark Pharmaceuticals Limited的熱門網域平均頁面瀏覽量
了解Glenmark Pharmaceuticals Limited如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自Glenmark Pharmaceuticals Limited
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Glenmark group has issues with recall for multiple lots.Glenmark Pharmaceuticals Inc. has initiated a recall for multiple lots of its bisoprolol fumarate and hydrochlorothiazide tablets, sold under the brand name Ziac, after discovering they may have been cross-contaminated with another drug.
12月 7, 2025閱讀更多
新聞Glenmark group launched Nebzmart GFB Smartules and Glenmark Airz FB Smartules on Nov 25th '25.Mumbai, India, 25 November 2025: Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global pharmaceutical company, today announced the launch of Nebzmart(R) GFB Smartules(R) and Glenmark Airz(R) FB Smartules(R), the world's first nebulized, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
11月 25, 2025閱讀更多
新聞Glenmark group partnered with Hengrui on Sep 24th '25.Glenmark Pharmaceuticals Ltd on Wednesday announced signing of an exclusive licence and collaboration pact with Hengrui Pharma for development and commercialisation of Trastuzumab Rezetecan that is aimed at treating different types of cancer.
9月 24, 2025閱讀更多
查看所有Glenmark Pharmaceuticals Limited信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。